

BIOGRAPHICAL SKETCH
Complete for each professional associated with the project

Name: *[Last, First, Middle Initial(s), Degree(s)]*
 Damiano Paolicelli, MD, PhD

Position/Title:
 Consultant Neurologist

Education

[Begin with baccalaureate or other professional education and include postdoctoral training]

Institution and Location	Degree	Year Conferred	Field of Study
University of Bari "Aldo Moro"	MD	1993	Research Thesis on the following topic "Multivariate Analysis of predictive prognostic Factors in Multiple Sclerosis"
University of Bari "Aldo Moro"	Neurologist	1998	Research Thesis on the following topic "Study of pharmacovigilance conducted in Southern Italy on patients with multiple sclerosis treated with interferon beta"
University of Rome "Sapienza"	PhD	2003	Neurobiology

Research and Professional Experience

[List in chronological order, previous employment, experience and honors]

2004 : Biannual Grant in Multiple Sclerosis, Department of Neurological and Psychiatric Sciences University of Bari, Bari, Italy (Post-marketing studies during DMDs therapy in Multiple Sclerosis)

2006: Biannual Grant in Multiple Sclerosis: at the Department of Neurological and Psychiatric Sciences University of Bari, Bari, Italy (The effect of Neutralizing antibodies anti-Interferon beta; An Italian database for Multiple Sclerosis)

Since 2012: Assistant Professor at the Faculty of Medicine, University of Bari scientific studies -Sector disciplinary MED / 26 Neurology

2013: Principal Investigator in the multicenter Italian study TRACER (Retrospective RebiSmart Adherence Rate data collection trough iMed)

Since June 2014: Reviewer for the scientific journal PlosOne and The Journal Neurological Sciences

Since October 2013:

Professor in Integrated Course of Neurological Sciences, V year, I semester, of the Degree in Medicine and Surgery, Sector MED26 Neurology, University of Bari

Since 2000:

Member of the Italian Study Group of Multiple Sclerosis; he helped formulate guidelines about the use and monitoring of neutralizing antibodies during therapy with Interferon Beta in patients with Multiple Sclerosis

Since 01/2016: Principal Investigator in the study "A phase 3B, 12-month, open-label, multi-center study to evaluate the efficacy and safety of BIIB019, Daclizumab high yield process (DAC HYP) in subjects with relapsing-remitting multiple sclerosis switching from Natalizumab" Protocol number 205MS305

Since 10/2016: Principal Investigator in the study "A Cross sectional survey of the Occurrence and Clinical Factors of Modifying Therapy (DMT) in relapsing Remitting Multiple Sclerosis (RRMS) Patients (SWITCH Study)" Protocollo n. DIREGL07914/SWITCH

Publications

For each investigator, provide complete bibliographic citations for selected **publications related to the topic of this application**. DO NOT exceed one page for each individual.

1. Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study
Frisullo G; Calabrese M; Tortorella C; et al.
MULTIPLE SCLEROSIS JOURNAL Volume: 20 Issue: 9 Pages: 1265-1268 Published: AUG 2014
2. A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy
Annovazzi P; Tomassini V ; Bodini B ; et al.
NEUROLOGICAL SCIENCES Volume: 34 Issue: 2 Pages: 197-203 Published: FEB 2013

Firma

